Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

Jimin Hwang; Se Bee Lee; Seung Won Lee; Min Ho Lee; Ai Koyanagi; Louis Jacob; Kalthoum Tizaoui; Dong Keon Yon; Jae Il Shin; Lee Smith

doi:10.1016/j.jaut.2021.102681

Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

Jimin Hwang, Se Bee Lee, Seung Won Lee, Min Ho Lee, Ai Koyanagi, Louis Jacob, Kalthoum Tizaoui, Dong Keon Yon, Jae Il Shin, Lee Smith

Department of Pediatrics

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV.2.S (Janssen/Johnson & Johnson) and ChAdOx1 nCoV-19 (Astra-Zeneca). We found that CVT after Ad26.COV.2.S vaccination presents later with similar symptoms compared to CVT after administration of ChAdOx1 nCoV-19, albeit with more thrombosis and intracerebral hemorrhage, lower D-dimer and aPTT levels but similar mortality. These findings could help guide clinical assessment and management of CVT after COVID-19 vaccination.

Original language	English
Article number	102681
Journal	Journal of Autoimmunity
Volume	122
DOIs	https://doi.org/10.1016/j.jaut.2021.102681
Publication status	Published - 2021 Aug

Bibliographical note

Funding Information:
We thank Elena Dragioti and Joaquim Radua for their valuable discussions and feedback.

Publisher Copyright:
© 2021 Elsevier Ltd

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jaut.2021.102681

Cite this

@article{4dbd46ed4c5c4b518a33b2098fd60910,

title = "Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines",

abstract = "Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV.2.S (Janssen/Johnson & Johnson) and ChAdOx1 nCoV-19 (Astra-Zeneca). We found that CVT after Ad26.COV.2.S vaccination presents later with similar symptoms compared to CVT after administration of ChAdOx1 nCoV-19, albeit with more thrombosis and intracerebral hemorrhage, lower D-dimer and aPTT levels but similar mortality. These findings could help guide clinical assessment and management of CVT after COVID-19 vaccination.",

author = "Jimin Hwang and Lee, {Se Bee} and Lee, {Seung Won} and Lee, {Min Ho} and Ai Koyanagi and Louis Jacob and Kalthoum Tizaoui and Yon, {Dong Keon} and Shin, {Jae Il} and Lee Smith",

note = "Funding Information: We thank Elena Dragioti and Joaquim Radua for their valuable discussions and feedback. Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2021",

month = aug,

doi = "10.1016/j.jaut.2021.102681",

language = "English",

volume = "122",

journal = "Journal of Autoimmunity",

issn = "0896-8411",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

AU - Hwang, Jimin

AU - Lee, Se Bee

AU - Lee, Seung Won

AU - Lee, Min Ho

AU - Koyanagi, Ai

AU - Jacob, Louis

AU - Tizaoui, Kalthoum

AU - Yon, Dong Keon

AU - Shin, Jae Il

AU - Smith, Lee

PY - 2021/8

Y1 - 2021/8

N2 - Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV.2.S (Janssen/Johnson & Johnson) and ChAdOx1 nCoV-19 (Astra-Zeneca). We found that CVT after Ad26.COV.2.S vaccination presents later with similar symptoms compared to CVT after administration of ChAdOx1 nCoV-19, albeit with more thrombosis and intracerebral hemorrhage, lower D-dimer and aPTT levels but similar mortality. These findings could help guide clinical assessment and management of CVT after COVID-19 vaccination.

AB - Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV.2.S (Janssen/Johnson & Johnson) and ChAdOx1 nCoV-19 (Astra-Zeneca). We found that CVT after Ad26.COV.2.S vaccination presents later with similar symptoms compared to CVT after administration of ChAdOx1 nCoV-19, albeit with more thrombosis and intracerebral hemorrhage, lower D-dimer and aPTT levels but similar mortality. These findings could help guide clinical assessment and management of CVT after COVID-19 vaccination.

UR - http://www.scopus.com/inward/record.url?scp=85107905698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107905698&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2021.102681

DO - 10.1016/j.jaut.2021.102681

M3 - Article

C2 - 34139631

AN - SCOPUS:85107905698

SN - 0896-8411

VL - 122

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

M1 - 102681

ER -

Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this